Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NKT5097 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on NKT5097, a putative dual CDK2/4 degrader (Jun 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NKT5097 | NKT-5097|NKT 5097 | CDK2/4 Inhibitor 1 | Limited information is currently available on NKT5097, a putative dual CDK2/4 degrader (Jun 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07029399 | Phase I | NKT5097 | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |